Short-Term Prediction of Preeclampsia in Chinese Women Using the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio: A Sub-Analysis of the PROGNOSIS Asia Study.
China
placental growth factor
prediction
preeclampsia
soluble fms-like tyrosine kinase 1
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
03
2021
accepted:
20
07
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
10
9
2021
Statut:
epublish
Résumé
The diagnosis of preeclampsia in China currently relies on limited clinical signs and unspecific laboratory findings. These are inadequate predictors of preeclampsia development, limiting early diagnosis and appropriate management. Previously, the Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia Study (PROGNOSIS) and PROGNOSIS Asia demonstrated that a soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio of ≤38 can be used to rule out preeclampsia within 1 week, with negative predictive values of 99.3 and 98.6%, respectively. This is an exploratory sub-analysis of the Chinese cohort (
Identifiants
pubmed: 34497833
doi: 10.3389/fcvm.2021.602560
pmc: PMC8419517
doi:
Types de publication
Journal Article
Langues
eng
Pagination
602560Informations de copyright
Copyright © 2021 Gao, Huang, Di, Dong, Gou, Shi, Wang, Dietl, Grill and Hund.
Déclaration de conflit d'intérêts
AD and SG are employees of Roche Diagnostics GmbH. MH is an employee of Roche Diagnostics International Ltd and holds stock in F. Hoffmann-La Roche. MH also reports being an inventor of patents related to sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia in pregnant women within a certain time period PCT/EP2013/063115 and the dynamic of sFlt-1 or endoglin/PlGF ratio as indicator for imminent preeclampsia and HELLP syndrome PCT/EP2012/072157. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pregnancy Hypertens. 2014 Apr;4(2):97-104
pubmed: 26104417
Am J Obstet Gynecol. 2010 Feb;202(2):161.e1-161.e11
pubmed: 19850276
Clin Chem Lab Med. 2020 Apr 01;59(3):e87-e89
pubmed: 32238604
Hypertension. 2019 Oct;74(4):983-990
pubmed: 31401877
J Hum Hypertens. 2014 Nov;28(11):694-8
pubmed: 24430700
Am J Obstet Gynecol. 2007 Mar;196(3):239.e1-6
pubmed: 17346536
Hypertension. 2020 Apr;75(4):918-926
pubmed: 32063058
Obstet Gynecol. 2001 Feb;97(2):261-7
pubmed: 11165592
Hypertens Res. 2021 Jul;44(7):813-821
pubmed: 33727707
N Engl J Med. 2016 Jan 7;374(1):83-4
pubmed: 26735997
Dis Markers. 2019 Jul 16;2019:6270187
pubmed: 31396294
Am J Obstet Gynecol. 2012 Jan;206(1):58.e1-8
pubmed: 22000672
BMJ. 2006 Feb 25;332(7539):463-8
pubmed: 16497761
Ultrasound Obstet Gynecol. 2019 Mar;53(3):367-375
pubmed: 30014562
N Engl J Med. 2016 Jan 7;374(1):13-22
pubmed: 26735990
Semin Perinatol. 2009 Jun;33(3):130-7
pubmed: 19464502
BMJ. 2013 Nov 07;347:f6564
pubmed: 24201165
Lancet Glob Health. 2016 Feb;4(2):e109-18
pubmed: 26795603
Hypertension. 2019 Jul;74(1):164-172
pubmed: 31188674
N Engl J Med. 2006 Sep 7;355(10):992-1005
pubmed: 16957146
Nat Rev Nephrol. 2014 Aug;10(8):466-80
pubmed: 25003615
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S281-S286
pubmed: 30831776
Clin Chem Lab Med. 2019 Aug 27;57(9):1339-1348
pubmed: 31323000